---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-054003"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:16:54.200418+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aldeyra advances new RASP modulators ADX-743, ADX-248, ADX-631; pediatric ADX-629 top-line results expected 2025

## Summary
- ADX-629 advanced to pediatric cohort in Sjögren-Larsson Syndrome Phase 2; top-line results from ~5 patients expected 2025.
- Novel RASP modulator ADX-743 entered IND-enabling studies for obesity; IND submission planned 2025.
- ADX-248 selected over ADX-246 for Phase 1/2 in atopic dermatitis; Phase 1 to start H2 2024.
- ADX-631 initiated preclinical testing in retinal disease; IND submission for dry AMD/geographic atrophy expected H1 2025.
- Investor roundtable webcast June 20, 2024 at 8:00 am ET to discuss these pipeline updates.

## SEC filing metadata
- accession: 0001213900-24-054003
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000121390024054003/0001213900-24-054003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000121390024054003/ea0208142-8k_aldeyra.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-054003
- JSON: https://secwatch.observer/filing/0001213900-24-054003.json
- Plain text: https://secwatch.observer/filing/0001213900-24-054003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.